Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a clonal disorder in which cells of the myeloid lineage undergo massive clonal expansion. The disease progresses through three distinct phases — chronic phase, accelerated phase, and blast crisis — during which the leukemic clone progressively loses its ability to d...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2001-04, Vol.344 (14), p.1031-1037 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1037 |
|---|---|
| container_issue | 14 |
| container_start_page | 1031 |
| container_title | The New England journal of medicine |
| container_volume | 344 |
| creator | Druker, Brian J Talpaz, Moshe Resta, Debra J Peng, Bin Buchdunger, Elisabeth Ford, John M Lydon, Nicholas B Kantarjian, Hagop Capdeville, Renaud Ohno-Jones, Sayuri Sawyers, Charles L |
| description | Chronic myeloid leukemia (CML) is a clonal disorder in which cells of the myeloid lineage undergo massive clonal expansion. The disease progresses through three distinct phases — chronic phase, accelerated phase, and blast crisis — during which the leukemic clone progressively loses its ability to differentiate.
1
,
2
Current therapies include allogeneic bone marrow transplantation and drug regimens including interferon alfa.
3
,
4
Interferon alfa prolongs overall survival but has considerable adverse effects. Allogeneic bone marrow transplantation, the only curative treatment for CML, is associated with substantial morbidity and mortality and is limited to patients for whom a suitable donor is available. . . . |
| doi_str_mv | 10.1056/NEJM200104053441401 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17879355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17879355</sourcerecordid><originalsourceid>FETCH-LOGICAL-c675t-b70155865e885061f003f4345f3f5d455695b6a2284cb25d12581b2e636029893</originalsourceid><addsrcrecordid>eNp9kV-L1DAUxYMo7rj6CQQJCr5INf9u2j7uDrPr6qyCuz6XNL1hMrbpmLQP_fZmmUFBxLwEcn_n3ntyCHnJ2XvOQH_4svl0KxjjTDGQSnHF-COy4iBloRTTj8mKMVEVqqzlGXmW0p7lw1X9lJxxLqqyLsWKuI1z3hq7UBM6emccTgsdHTX07oDW5xq9CTvf-mmMD-_TDunl-ltxcbml90sckw9IP_tgElIf6HoXx5A1twv2o-_oFucfOHjznDxxpk_44nSfk-9Xm_v1x2L79fpmfbEtrC5hKtqScYBKA1YVMM0dY9IpqcBJB50C0DW02ghRKdsK6LiAircCtdRM1FUtz8nbY99DHH_OmKZm8Mli35uA45waXmbfEiCDr_8C9-McQ96tEULWSgnFMySPkM1GU0TXHKIfTFwazpqHDJp_ZJBVr06t53bA7o_m9OkZeHMCTLKmd9EE69NvrlYim8nUuyM1DKkJuB_-O_QXHTuV6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223944241</pqid></control><display><type>article</type><title>Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine Current</source><creator>Druker, Brian J ; Talpaz, Moshe ; Resta, Debra J ; Peng, Bin ; Buchdunger, Elisabeth ; Ford, John M ; Lydon, Nicholas B ; Kantarjian, Hagop ; Capdeville, Renaud ; Ohno-Jones, Sayuri ; Sawyers, Charles L</creator><creatorcontrib>Druker, Brian J ; Talpaz, Moshe ; Resta, Debra J ; Peng, Bin ; Buchdunger, Elisabeth ; Ford, John M ; Lydon, Nicholas B ; Kantarjian, Hagop ; Capdeville, Renaud ; Ohno-Jones, Sayuri ; Sawyers, Charles L</creatorcontrib><description>Chronic myeloid leukemia (CML) is a clonal disorder in which cells of the myeloid lineage undergo massive clonal expansion. The disease progresses through three distinct phases — chronic phase, accelerated phase, and blast crisis — during which the leukemic clone progressively loses its ability to differentiate.
1
,
2
Current therapies include allogeneic bone marrow transplantation and drug regimens including interferon alfa.
3
,
4
Interferon alfa prolongs overall survival but has considerable adverse effects. Allogeneic bone marrow transplantation, the only curative treatment for CML, is associated with substantial morbidity and mortality and is limited to patients for whom a suitable donor is available. . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM200104053441401</identifier><identifier>PMID: 11287972</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject><![CDATA[Abl gene ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacokinetics ; BCR gene ; Benzamides ; Biological and medical sciences ; Blood Cell Count ; Bone marrow ; Chemotherapy ; Dose-Response Relationship, Drug ; Drug therapy ; Enzyme Inhibitors - administration & dosage ; Enzyme Inhibitors - adverse effects ; Enzyme Inhibitors - pharmacokinetics ; Female ; Fusion Proteins, bcr-abl - antagonists & inhibitors ; Fusion Proteins, bcr-abl - metabolism ; Humans ; Imatinib Mesylate ; Interferon ; Interferon-alpha - therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Phosphorylation ; Piperazines - administration & dosage ; Piperazines - adverse effects ; Piperazines - pharmacokinetics ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Protein-Tyrosine Kinases - metabolism ; Proteins ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Pyrimidines - pharmacokinetics ; Recurrence ; Remission Induction - methods ; STI571 ; Transplants & implants]]></subject><ispartof>The New England journal of medicine, 2001-04, Vol.344 (14), p.1031-1037</ispartof><rights>Copyright © 2001 Massachusetts Medical Society. All rights reserved.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c675t-b70155865e885061f003f4345f3f5d455695b6a2284cb25d12581b2e636029893</citedby><cites>FETCH-LOGICAL-c675t-b70155865e885061f003f4345f3f5d455695b6a2284cb25d12581b2e636029893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM200104053441401$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM200104053441401$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=942029$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11287972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Druker, Brian J</creatorcontrib><creatorcontrib>Talpaz, Moshe</creatorcontrib><creatorcontrib>Resta, Debra J</creatorcontrib><creatorcontrib>Peng, Bin</creatorcontrib><creatorcontrib>Buchdunger, Elisabeth</creatorcontrib><creatorcontrib>Ford, John M</creatorcontrib><creatorcontrib>Lydon, Nicholas B</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Capdeville, Renaud</creatorcontrib><creatorcontrib>Ohno-Jones, Sayuri</creatorcontrib><creatorcontrib>Sawyers, Charles L</creatorcontrib><title>Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Chronic myeloid leukemia (CML) is a clonal disorder in which cells of the myeloid lineage undergo massive clonal expansion. The disease progresses through three distinct phases — chronic phase, accelerated phase, and blast crisis — during which the leukemic clone progressively loses its ability to differentiate.
1
,
2
Current therapies include allogeneic bone marrow transplantation and drug regimens including interferon alfa.
3
,
4
Interferon alfa prolongs overall survival but has considerable adverse effects. Allogeneic bone marrow transplantation, the only curative treatment for CML, is associated with substantial morbidity and mortality and is limited to patients for whom a suitable donor is available. . . .</description><subject>Abl gene</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>BCR gene</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Blood Cell Count</subject><subject>Bone marrow</subject><subject>Chemotherapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Enzyme Inhibitors - administration & dosage</subject><subject>Enzyme Inhibitors - adverse effects</subject><subject>Enzyme Inhibitors - pharmacokinetics</subject><subject>Female</subject><subject>Fusion Proteins, bcr-abl - antagonists & inhibitors</subject><subject>Fusion Proteins, bcr-abl - metabolism</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphorylation</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - pharmacokinetics</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Protein-Tyrosine Kinases - metabolism</subject><subject>Proteins</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - pharmacokinetics</subject><subject>Recurrence</subject><subject>Remission Induction - methods</subject><subject>STI571</subject><subject>Transplants & implants</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kV-L1DAUxYMo7rj6CQQJCr5INf9u2j7uDrPr6qyCuz6XNL1hMrbpmLQP_fZmmUFBxLwEcn_n3ntyCHnJ2XvOQH_4svl0KxjjTDGQSnHF-COy4iBloRTTj8mKMVEVqqzlGXmW0p7lw1X9lJxxLqqyLsWKuI1z3hq7UBM6emccTgsdHTX07oDW5xq9CTvf-mmMD-_TDunl-ltxcbml90sckw9IP_tgElIf6HoXx5A1twv2o-_oFucfOHjznDxxpk_44nSfk-9Xm_v1x2L79fpmfbEtrC5hKtqScYBKA1YVMM0dY9IpqcBJB50C0DW02ghRKdsK6LiAircCtdRM1FUtz8nbY99DHH_OmKZm8Mli35uA45waXmbfEiCDr_8C9-McQ96tEULWSgnFMySPkM1GU0TXHKIfTFwazpqHDJp_ZJBVr06t53bA7o_m9OkZeHMCTLKmd9EE69NvrlYim8nUuyM1DKkJuB_-O_QXHTuV6Q</recordid><startdate>20010405</startdate><enddate>20010405</enddate><creator>Druker, Brian J</creator><creator>Talpaz, Moshe</creator><creator>Resta, Debra J</creator><creator>Peng, Bin</creator><creator>Buchdunger, Elisabeth</creator><creator>Ford, John M</creator><creator>Lydon, Nicholas B</creator><creator>Kantarjian, Hagop</creator><creator>Capdeville, Renaud</creator><creator>Ohno-Jones, Sayuri</creator><creator>Sawyers, Charles L</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>20010405</creationdate><title>Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia</title><author>Druker, Brian J ; Talpaz, Moshe ; Resta, Debra J ; Peng, Bin ; Buchdunger, Elisabeth ; Ford, John M ; Lydon, Nicholas B ; Kantarjian, Hagop ; Capdeville, Renaud ; Ohno-Jones, Sayuri ; Sawyers, Charles L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c675t-b70155865e885061f003f4345f3f5d455695b6a2284cb25d12581b2e636029893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Abl gene</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>BCR gene</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Blood Cell Count</topic><topic>Bone marrow</topic><topic>Chemotherapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Enzyme Inhibitors - administration & dosage</topic><topic>Enzyme Inhibitors - adverse effects</topic><topic>Enzyme Inhibitors - pharmacokinetics</topic><topic>Female</topic><topic>Fusion Proteins, bcr-abl - antagonists & inhibitors</topic><topic>Fusion Proteins, bcr-abl - metabolism</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphorylation</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - pharmacokinetics</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Protein-Tyrosine Kinases - metabolism</topic><topic>Proteins</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - pharmacokinetics</topic><topic>Recurrence</topic><topic>Remission Induction - methods</topic><topic>STI571</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Druker, Brian J</creatorcontrib><creatorcontrib>Talpaz, Moshe</creatorcontrib><creatorcontrib>Resta, Debra J</creatorcontrib><creatorcontrib>Peng, Bin</creatorcontrib><creatorcontrib>Buchdunger, Elisabeth</creatorcontrib><creatorcontrib>Ford, John M</creatorcontrib><creatorcontrib>Lydon, Nicholas B</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Capdeville, Renaud</creatorcontrib><creatorcontrib>Ohno-Jones, Sayuri</creatorcontrib><creatorcontrib>Sawyers, Charles L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Druker, Brian J</au><au>Talpaz, Moshe</au><au>Resta, Debra J</au><au>Peng, Bin</au><au>Buchdunger, Elisabeth</au><au>Ford, John M</au><au>Lydon, Nicholas B</au><au>Kantarjian, Hagop</au><au>Capdeville, Renaud</au><au>Ohno-Jones, Sayuri</au><au>Sawyers, Charles L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2001-04-05</date><risdate>2001</risdate><volume>344</volume><issue>14</issue><spage>1031</spage><epage>1037</epage><pages>1031-1037</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Chronic myeloid leukemia (CML) is a clonal disorder in which cells of the myeloid lineage undergo massive clonal expansion. The disease progresses through three distinct phases — chronic phase, accelerated phase, and blast crisis — during which the leukemic clone progressively loses its ability to differentiate.
1
,
2
Current therapies include allogeneic bone marrow transplantation and drug regimens including interferon alfa.
3
,
4
Interferon alfa prolongs overall survival but has considerable adverse effects. Allogeneic bone marrow transplantation, the only curative treatment for CML, is associated with substantial morbidity and mortality and is limited to patients for whom a suitable donor is available. . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>11287972</pmid><doi>10.1056/NEJM200104053441401</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2001-04, Vol.344 (14), p.1031-1037 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17879355 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine Current |
| subjects | Abl gene Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics BCR gene Benzamides Biological and medical sciences Blood Cell Count Bone marrow Chemotherapy Dose-Response Relationship, Drug Drug therapy Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Enzyme Inhibitors - pharmacokinetics Female Fusion Proteins, bcr-abl - antagonists & inhibitors Fusion Proteins, bcr-abl - metabolism Humans Imatinib Mesylate Interferon Interferon-alpha - therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Medical sciences Middle Aged Pharmacology. Drug treatments Phosphorylation Piperazines - administration & dosage Piperazines - adverse effects Piperazines - pharmacokinetics Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - metabolism Proteins Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - pharmacokinetics Recurrence Remission Induction - methods STI571 Transplants & implants |
| title | Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A56%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20a%20Specific%20Inhibitor%20of%20the%20BCR-ABL%20Tyrosine%20Kinase%20in%20Chronic%20Myeloid%20Leukemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Druker,%20Brian%20J&rft.date=2001-04-05&rft.volume=344&rft.issue=14&rft.spage=1031&rft.epage=1037&rft.pages=1031-1037&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM200104053441401&rft_dat=%3Cproquest_cross%3E17879355%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223944241&rft_id=info:pmid/11287972&rfr_iscdi=true |